Blood test software could spot pancreatic cancer early in High-Risk groups
NCT ID NCT06549725
First seen May 05, 2026 · Last updated Jun 23, 2026 · Updated 12 times
Summary
This study is testing a software called Lipidica that analyzes fats in the blood to help screen for pancreatic cancer. Researchers will compare results from people with pancreatic cancer to those at high risk (due to family history or genetic factors) to see if the software can tell them apart. About 419 participants will provide blood samples and undergo imaging tests like endoscopic ultrasound or MRI. The goal is to see if this non-invasive approach can improve early detection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fakultni Thomayerova nemocnice
RECRUITINGPrague, Czechia
Contact Email: •••••@•••••
Contact
-
Fakultni nemocnice Brno
RECRUITINGBrno, Czechia
Contact Email: •••••@•••••
Contact
-
Fakultni nemocnice Bulovka
RECRUITINGPrague, Czechia
Contact Email: •••••@•••••
Contact
-
Fakultni nemocnice Hradec Kralove
RECRUITINGHradec Králové, Czechia
Contact
Contact Email: •••••@•••••
-
Fakultni nemocnice Kralovske Vinohrady
RECRUITINGPrague, Czechia
Contact
Contact Email: •••••@•••••
Contact
-
Fakultni nemocnice Olomouc
RECRUITINGOlomouc, Czechia
Contact Email: •••••@•••••
Contact
-
Fakultni nemocnice Plzen
RECRUITINGPilsen, Czechia
Contact Email: •••••@•••••
Contact
-
Fakultni nemocnice u sv. Anny
RECRUITINGBrno, Czechia
Contact Email: •••••@•••••
Contact
-
Institut klinicke a experimentalni mediciny
RECRUITINGPrague, Czechia
Contact Email: •••••@•••••
Contact
-
Masarykova nemocnice v Usti nad Labem
RECRUITINGÚstí nad Labem, Czechia
Contact Email: •••••@•••••
Contact
-
Masarykuv onkologicky ustav
RECRUITINGBrno, Czechia
Contact
Contact Email: •••••@•••••
-
Nemocnice Ceske Budejovice
RECRUITINGČeské Budějovice, Czechia
Contact Email: •••••@•••••
Contact
-
Nemocnice Jablonec nad Nisou
NOT_YET_RECRUITINGJablonec nad Nisou, Czechia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Nemocnice Pardubickeho kraje
RECRUITINGPardubice, Czechia
Contact Email: •••••@•••••
Contact
-
Ustredni vojenska nemocnice
RECRUITINGPrague, Czechia, Czechia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Vseobecna fakultni nemocnice
RECRUITINGPrague, Czechia
Contact
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lipidica 1.0 software (medical device software for analyzing lipidomic data)
What this could lead to
If successful, this could provide a simple blood test to screen for pancreatic cancer in people at high risk, potentially catching the disease earlier.
What could go wrong
This is an early-stage study focused on accuracy, not treatment. The software may not be sensitive or specific enough to reliably detect cancer, and results may not apply to the general population.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.